Yvette Drew

6.1k total citations · 1 hit paper
68 papers, 2.3k citations indexed

About

Yvette Drew is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Yvette Drew has authored 68 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 32 papers in Molecular Biology and 16 papers in Reproductive Medicine. Recurrent topics in Yvette Drew's work include PARP inhibition in cancer therapy (45 papers), DNA Repair Mechanisms (20 papers) and Ovarian cancer diagnosis and treatment (15 papers). Yvette Drew is often cited by papers focused on PARP inhibition in cancer therapy (45 papers), DNA Repair Mechanisms (20 papers) and Ovarian cancer diagnosis and treatment (15 papers). Yvette Drew collaborates with scholars based in United Kingdom, United States and Canada. Yvette Drew's co-authors include Nicola J. Curtin, Alice Bradbury, Rebecca Kristeleit, Jonathan A. Ledermann, Ruth Plummer, Zdeněk Hostomský, Stuart Rundle, Asima Mukhopadhyay, Richard J. Edmondson and Suzanne Kyle and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and JNCI Journal of the National Cancer Institute.

In The Last Decade

Yvette Drew

68 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

2024 54 citations Yvette Drew, Frank T. Zenke et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yvette Drew United Kingdom	22	1.8k	1.4k	625	333	328	68	2.3k
Maria Orr United Kingdom	12	1.3k 0.7×	794 0.6×	702 1.1×	473 1.4×	156 0.5×	16	1.8k
Andrea E. Wahner Hendrickson United States	15	839 0.5×	633 0.5×	405 0.6×	113 0.3×	164 0.5×	55	1.3k
Marsela Braunstein Canada	11	450 0.3×	638 0.5×	485 0.8×	82 0.2×	320 1.0×	15	1.4k
Amèlie Renaud United States	6	2.0k 1.1×	1.7k 1.2×	246 0.4×	265 0.8×	262 0.8×	7	2.4k
Patrick G. Pilié United States	13	1.1k 0.6×	1.1k 0.8×	91 0.1×	135 0.4×	227 0.7×	43	1.8k
Janneke E. Jaspers Netherlands	15	1.5k 0.9×	1.4k 1.0×	154 0.2×	388 1.2×	208 0.6×	17	2.0k
Elizabeth Ruth Plummer United Kingdom	19	961 0.5×	836 0.6×	123 0.2×	152 0.5×	137 0.4×	69	1.3k
Bose Kochupurakkal United States	16	810 0.5×	1.0k 0.7×	100 0.2×	97 0.3×	117 0.4×	44	1.4k
Tomoko Freshwater United States	13	1.0k 0.6×	783 0.6×	112 0.2×	73 0.2×	226 0.7×	27	1.5k

Countries citing papers authored by Yvette Drew

Since Specialization

Citations

This map shows the geographic impact of Yvette Drew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvette Drew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvette Drew more than expected).

Fields of papers citing papers by Yvette Drew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvette Drew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvette Drew. The network helps show where Yvette Drew may publish in the future.

Co-authorship network of co-authors of Yvette Drew

This figure shows the co-authorship network connecting the top 25 collaborators of Yvette Drew. A scholar is included among the top collaborators of Yvette Drew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvette Drew. Yvette Drew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jamieson, Amy, Dawn R. Cochrane, J. Maxwell Douglas, et al.. (2024). Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers. Clinical Cancer Research. 30(11). 2461–2474. 11 indexed citations

Drew, Yvette, Frank T. Zenke, & Nicola J. Curtin. (2024). DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nature Reviews Drug Discovery. 24(1). 19–39. 54 indexed citations breakdown →

Davies, Janine M., et al.. (2023). Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).. Journal of Clinical Oncology. 41(16_suppl). e17547–e17547. 1 indexed citations

Rae, S., E. Ruth Plummer, Linda Hogarth, et al.. (2023). Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. Journal of Cancer Research and Clinical Oncology. 149(18). 16355–16363. 1 indexed citations

Helali, Aya El, Ruth Plummer, Gordon C. Jayson, et al.. (2022). A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer. 127(1). 92–101. 9 indexed citations

Saha, Sweta Sharma, Alice Bradbury, R.L. Robinson, et al.. (2021). Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers. 13(6). 1420–1420. 8 indexed citations

Morrison, Jo, Janos Balega, Lynn Buckley, et al.. (2021). British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 270. 50–89. 76 indexed citations

Tomaszewska‐Kiecana, Monika, Rodryg Ramlau, Yvette Drew, et al.. (2021). Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology. 88(2). 259–270. 11 indexed citations

Robinson, Harry M., et al.. (2020). Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm. International Journal of Gynecological Pathology. 40(2). 190–195. 5 indexed citations

10.

Ramalingam, Sundar, Juanita Lopez, Morten Mau‐Sørensen, et al.. (2019). OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S209–S209. 12 indexed citations

11.

Curtin, Nicola J., Yvette Drew, & Sweta Sharma Saha. (2019). Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nature Reviews Clinical Oncology. 16(12). 725–726. 20 indexed citations

12.

Kristeleit, Rebecca, Geoffrey I. Shapiro, Howard A. Burris, et al.. (2017). A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research. 23(15). 4095–4106. 186 indexed citations

13.

Vergote, Ignace, Emma Dean, Ulrik Lassen, et al.. (2017). A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology. 28. v330–v331. 6 indexed citations

14.

Helali, Aya El, Ruth Plummer, Gordon C. Jayson, et al.. (2017). A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours. Annals of Oncology. 28. v128–v128. 5 indexed citations

15.

Ledermann, Jonathan A., Yvette Drew, & Rebecca Kristeleit. (2016). Homologous recombination deficiency and ovarian cancer. European Journal of Cancer. 60. 49–58. 193 indexed citations

16.

Drew, Yvette, Jonathan A. Ledermann, Geoff Hall, et al.. (2016). Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer. 114(7). 723–730. 126 indexed citations

17.

Drew, Yvette. (2015). The development of PARP inhibitors in ovarian cancer: from bench to bedside. British Journal of Cancer. 113(S1). S3–S9. 36 indexed citations

18.

Roda, Desamparados, Yvette Drew, Analía Azaro, et al.. (2015). A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).. Journal of Clinical Oncology. 33(15_suppl). 2513–2513. 1 indexed citations

19.

Mukhopadhyay, Asima, Ahmed Elattar, Sarah Wilkinson, et al.. (2010). Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research. 16(8). 2344–2351. 207 indexed citations

20.

Rozanska, Agata, Huw D. Thomas, Evan A. Mulligan, et al.. (2009). Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research. 15(4). 1241–1249. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact